Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Baylor Genetics | RCV001332872 | SCV001525311 | uncertain significance | Congenital myasthenic syndrome 19 | 2019-03-26 | criteria provided, single submitter | clinical testing | This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. |
Labcorp Genetics |
RCV001865769 | SCV002196558 | uncertain significance | not provided | 2022-10-17 | criteria provided, single submitter | clinical testing | This sequence change replaces aspartic acid, which is acidic and polar, with glutamic acid, which is acidic and polar, at codon 180 of the COL13A1 protein (p.Asp180Glu). This variant is present in population databases (rs202115626, gnomAD 0.08%). This variant has not been reported in the literature in individuals affected with COL13A1-related conditions. ClinVar contains an entry for this variant (Variation ID: 1031125). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV002546603 | SCV003740199 | uncertain significance | Inborn genetic diseases | 2022-12-16 | criteria provided, single submitter | clinical testing | The c.540C>A (p.D180E) alteration is located in exon 8 (coding exon 8) of the COL13A1 gene. This alteration results from a C to A substitution at nucleotide position 540, causing the aspartic acid (D) at amino acid position 180 to be replaced by a glutamic acid (E). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Revvity Omics, |
RCV001332872 | SCV003833409 | uncertain significance | Congenital myasthenic syndrome 19 | 2019-08-02 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV001865769 | SCV005411029 | uncertain significance | not provided | 2023-09-27 | criteria provided, single submitter | clinical testing |